Successful pregnancy after porcine bioartificial liver treatment and liver transplantation for fulminant hepatic failure

Scott L. Nyberg, Eileen J. Hay, Kirk D. Ramin, Charles B. Rosen

Research output: Contribution to journalArticlepeer-review

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)169-170
Number of pages2
JournalLiver Transplantation
Issue number2
StatePublished - 2002

Bibliographical note

Funding Information:
After obtaining informed consent from the patient’s husband, she was randomized to the treatment arm of a prospective phase III trial of the HepatAssist liver support system sponsored by Circe Biomedical, Lexington, MA. This extracorporeal bioartificial liver (BAL) uses approximately 75 g of cryopreserved porcine hepatocytes and an activated charcoal column for therapy to the plasma fraction of blood.1 Her intracranial pressure and arterial ammonia level improved with the first BAL treatment from 34 to 10 mm Hg and 281 to 124 µg/dL, respectively.

Cite this